• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

Neuralink Will Change the World and Your Brain

Tech Letter

Founder of Tesla Elon Musk is on record confessing that it would be a “good idea” to bring his four businesses — Tesla, SpaceX, Neuralink, and The Boring Company — under a giant holding company.

Doing this would encourage more talented engineers to work for Musk and allow the four companies to combine human resources and marketing departments.

The synergies would be countless.

Most of you know three of the four, so let me explain to you about Neuralink.

In short, Neuralink Corporation is an American neurotechnology company developing implantable brain-machine interfaces.

You would think this is straight out of science fiction, but mark my word that in our lifetime, we could all be operating digital devices from our heads if Musk gets his way.

And he often does get his way.

Scary as it seems now, this will probably be the first of many artificial intelligence procedures to infuse humans with layers of artificial intelligence.

Musk believes humans will go the way of robot hybrid in the future because the natural development of competition is trending in that way and sadly, this direction in humanity is ultimately existential for every one of us.

Improvements in technology will periodically be announced and iterations will need to be adopted because software is upgraded.

Fortunately, we are nowhere close to the actual implementation of these neuro devices let alone trying to analyze the consumer and economic implications of this technology.

As for today and now, we are in the early innings and testing it out on pigs.

Better them and not me.

Neuralink’s dramatically simplified design for an implant that hopes to create brain-to-machine interfaces is a big deal and partly because of the star power backing the project that can literally move mountains.

The previous design consisted of a bean-shaped device that would sit behind the ear, but now it is the size of a large coin, and it goes in your skull.

I expect the final iteration to be a millimeter wide.

The in-brain device could enable humans with neurological conditions to control technology, such as phones or computers, with mere thoughts.

The other use case is solving neurological disorders from memory, hearing loss, and blindness to paralysis, depression, and brain damage which is a tad more altruistic.

The current prototype – referred to as version 0.9 – measures 23 millimeters by eight millimeters, and has 1024 electrode "threads" attached to it that are implanted into the brain.

It is designed to replace a coin-sized portion of the skull and sit flush so it would be physically unnoticeable. It would be inductively charged the same way you would wirelessly charge a smartwatch or a phone.

The surgical robot, which is programmed to insert the neural threads safely into the brain, was done by US design company Woke Studios.

Woke Studio’s robot would be able to insert the link in under an hour without general anesthesia, with the patient able to leave the hospital right away.

The robot will eventually do the entire surgery – so everything from the incision, removing the skull, inserting electrodes, placing the device, and then closing things up.

It will be completely automated.

Test pigs are being used to test the device which offers important insights into the process of inserting a chip into a brain.

The implant sends real-time signals from the pig’s brain whenever it touches something with its snout.

Described as "healthy and happy", one of the pigs demonstrated that it is possible to have multiple chips in your head at one time.

Musk also showed a pig that previously had a chip inserted into its brain, but had since been removed, to show that the procedure is reversible without any serious side effects.

Neuralink’s Breakthrough Device designation by FDA supports Musk’s neuroscience objectives. The startup is now preparing for its first human test case, pending required approvals, and further safety testing.

If this technology is green-lighted by the U.S. Federal Government, I envision a free for all into this technology from the likes of Facebook, Google, Apple, and Microsoft, and so on.

If you thought website “cookie tracking” is bad now, then once tech firms are granted access to consumers’ brains, it could open up a pandora's box of moral conflicts of interest, an avalanche of revenue opportunities, and lawsuits galore.

Look at the hesitation and disgruntlement of the health industry hoping to convince Americans to take two jabs of an mRNA vaccine in the arm and now think about trying to convince Americans to implant a brain in their head for the sake of competing.

Will American society really get to the point where Facebook is selling your “thoughts” to neural advertisers?

It’s scary to think about but that is the direction we are headed down for better or worse.

If you view this through the lens of big tech, battering down the hatches to get access to consumer’s “thoughts” is the holy grail of access points and revenue flow.

In 2021, humans still need to digest thoughts and carry out functions through fingers into a phone interface.

We have also allowed big tech into our home feeding them data through smart devices and virtual assistants like Amazon Alexa.

Getting rid of all that “fluff” and extracting data and behavioral results from the original source is potentially worth over 10 trillion dollars along with a recurring revenue source to infinity.

Not only will physical devices be useless at that point, but they will also spawn a mega cloud storage business that is hooked straight to the mind.

An economic analyst can digest how cloud companies like Amazon and Google would rake in the trillions by storing libraries of data that a mind can tap in at any time.

It really is a gigantic step that will digitize and computerize humans - big tech is first in line to reap the profits and literally control our brains.

Maybe by that time, the government will actually lift a finger and regulate since the current crop of Baby Boomers still have no idea what Facebook does and have been turning a blind eye.

This is the future – a future where we coexist with artificial intelligence.

 

neuralink

 

neuralink

https://www.madhedgefundtrader.com/wp-content/uploads/2020/12/neuralink-architecture.png 492 832 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-23 14:02:412021-08-01 02:54:29Neuralink Will Change the World and Your Brain
Mad Hedge Fund Trader

July 23, 2021 - Quote of the Day

Tech Letter

“When something is important enough, you do it even if the odds are not in your favor.” – Said Founder and CEO of Tesla and Neuralink Elon Musk

https://www.madhedgefundtrader.com/wp-content/uploads/2021/07/elon-musk.png 516 446 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-23 14:00:352021-07-23 16:12:23July 23, 2021 - Quote of the Day
Mad Hedge Fund Trader

July 23, 2021

Diary, Newsletter, Summary

Global Market Comments
July 23, 2021
Fiat Lux

Featured Trade:

(INDUSTRIES YOU WILL NEVER HEAR FROM ME ABOUT)
(AMZN), (DIS), (FB), (MSFT), (VIX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-23 09:04:052021-07-23 13:42:47July 23, 2021
MHFTR

July 23, 2021 - Quote of the Day

Diary, Newsletter, Quote of the Day

“The bulls have the run of the table here on oil,” said John Kilduff from Again Capital Partners.

Craps Table

https://www.madhedgefundtrader.com/wp-content/uploads/2015/12/Craps-Table.jpg 222 297 MHFTR https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png MHFTR2021-07-23 09:00:562021-07-23 13:41:22July 23, 2021 - Quote of the Day
Mad Hedge Fund Trader

July 22, 2021

Biotech Letter

 

Mad Hedge Biotech & Healthcare Letter
July 22, 2021
Fiat Lux

FEATURED TRADE:

(ANOTHER STEP CLOSER TO NEURO-VICTORY)
(BAYRY), (BIIB), (LLY), (SIOX), (RHHBY), (ABBV), (MRK), (PFE), (AZN)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-22 15:02:422021-07-22 16:52:09July 22, 2021
Mad Hedge Fund Trader

Another Step Closer to Neuro-Victory

Biotech Letter

First, Alzheimer’s. Now, Parkinson’s.

Companies working on neurodegenerative diseases are on a roll.

After Biogen’s (BIIB) work with Aduhelm, another biopharmaceutical company has made notable progress: Bayer (BAYRY).

Merely six weeks after DA01 landed in the clinic, Bayer’s Parkinson’s disease drug candidate is getting into the fast lane.

This marks one of the major pipeline candidates that the German company picked up from its $1 billion acquisition of Versant Ventures in 2019.

DA01 is described as a “pluripotent stem cell-derived dopaminergic neuron therapy.”

In layman’s terms, Bayer collects donor cells that have the ability to develop into any other cell type in the body.

It will then engineer these versatile cells to turn into neurons that have the capacity to produce the neurotransmitter dopamine—aka the chemical your nervous system uses to transmit messages to nerve cells.

Those engineered neurons will then be transplanted into a part of the brain, called the putamen, which is in charge of our movements and learning.

What we know so far is that the next phase of the trial will determine the safety and tolerability of the cell transplantation a year following the procedure.

This will also tell us more about the cell survival rate after the transplant and the motor effects a year or two following the procedure.

Like Biogen’s Alzheimer’s candidate, the fast-track designation with the FDA could open doors for a speedy review or even an accelerated approval for Bayer’s DA01.

Aside from transplanting engineered cells into patients’ brains, the company is also looking into other options for Parkinson’s.

In October 2020, it shelled out $2 billion upfront to acquire Asklepios BioPharmaceutical or AskBio for its gene therapy research on Parkinson’s.

Roughly 1 million people in the US are suffering from Parkinson’s disease—a number that’s greater than the combined number of patients diagnosed with Lou Gehrig’s disease, multiple sclerosis, and muscular dystrophy.

What’s worse is that this is expected to climb to 1.2 million by 2030.

In terms of treatment cost, the combined expenses for Parkinson’s, including medical bills and lost income, are estimated to reach about $52 billion annually in the US alone.

The medications alone already amount to an average of $2,500 per year, with therapeutic surgery reaching up to $100,000 per person.

This is why it comes as no surprise that several companies have been working towards figuring out a more potent treatment or even cure for Parkinson’s.

One of the frontrunners is Prevail Therapeutics, a New York-based biotechnology company that’s focused on developing a gene therapy for this disease.

Following a successful Series B financing round in 2019, in which it secured $50 million in investments, the company eventually attracted the attention of big pharma.

By December 2020, it was acquired by Eli Lilly (LLY) for $880 million with the promise to help the smaller biotech company develop three of its most promising Parkinson’s candidates.

Another Parkinson’s-centered biotech company is Axovant Gene Therapies, which has been working on a single-dose treatment for neurodegenerative disease.

Its pipeline proved to be promising, as seen in its $74.7 million public offering just last February 2020, with the company maintaining its solid footing amid the pandemic.

By November, it rebranded itself as Sio Gene Therapies (SIOX).

Outside the US is Irish biotech firm Inflazome, which is working on a unique treatment for Parkinson’s.

Unlike the other candidates, the goal of Inflazome’s drug is to directly deliver the treatment to the affected neurons. That is, it plans to pass through the blood-brain barrier.

Its research attracted the Michael J. Fox Foundation, which granted it $1 million in funding, in March 2019.

Since then, the company’s progress has attracted the attention of other major biopharmaceutical companies with Roche (RHHBY), ultimately landing the acquisition in September 2020.

Of course, talks about neurodegenerative diseases wouldn’t be complete without Biogen.

On top of its Alzheimer’s work, the Massachusetts biotechnology giant has been collaborating with San Francisco-based Parkinson’s company Denali Therapeutics.

The two have been working on the development of three small molecular drugs for $560 million in upfront payments plus $465 million in equity investment into the smaller biotech.

In addition to these, we’re still waiting on what the rest of the major biopharmaceutical companies would come up with in the future.

Given that the likes of AbbVie (ABBV), Merck (MRK), Pfizer (PFE), and AstraZeneca (AZN) have all signed up publicly via the Critical Path for Parkinson's (CPP) consortium to tackle this debilitating disease, it’s safe to say that there’s hope for the future of this sector.

First, Alzheimer’s. Now, Parkinson’s.

Companies working on neurodegenerative diseases are on a roll.

After Biogen’s (BIIB) work with Aduhelm, another biopharmaceutical company has made notable progress: Bayer (BAYRY).

Merely six weeks after DA01 landed in the clinic, Bayer’s Parkinson’s disease drug candidate is getting into the fast lane.

This marks one of the major pipeline candidates that the German company picked up from its $1 billion acquisition of Versant Ventures in 2019.

DA01 is described as a “pluripotent stem cell-derived dopaminergic neuron therapy.”

In layman’s terms, Bayer collects donor cells that have the ability to develop into any other cell type in the body.

It will then engineer these versatile cells to turn into neurons that have the capacity to produce the neurotransmitter dopamine—aka the chemical your nervous system uses to transmit messages to nerve cells.

Those engineered neurons will then be transplanted into a part of the brain, called the putamen, which is in charge of our movements and learning.

What we know so far is that the next phase of the trial will determine the safety and tolerability of the cell transplantation a year following the procedure.

This will also tell us more about the cell survival rate after the transplant and the motor effects a year or two following the procedure.

Like Biogen’s Alzheimer’s candidate, the fast-track designation with the FDA could open doors for a speedy review or even an accelerated approval for Bayer’s DA01.

Aside from transplanting engineered cells into patients’ brains, the company is also looking into other options for Parkinson’s.

In October 2020, it shelled out $2 billion upfront to acquire Asklepios BioPharmaceutical or AskBio for its gene therapy research on Parkinson’s.

Roughly 1 million people in the US are suffering from Parkinson’s disease—a number that’s greater than the combined number of patients diagnosed with Lou Gehrig’s disease, multiple sclerosis, and muscular dystrophy.

What’s worse is that this is expected to climb to 1.2 million by 2030.

In terms of treatment cost, the combined expenses for Parkinson’s, including medical bills and lost income, are estimated to reach about $52 billion annually in the US alone.

The medications alone already amount to an average of $2,500 per year, with therapeutic surgery reaching up to $100,000 per person.

This is why it comes as no surprise that several companies have been working towards figuring out a more potent treatment or even cure for Parkinson’s.

One of the frontrunners is Prevail Therapeutics, a New York-based biotechnology company that’s focused on developing a gene therapy for this disease.

Following a successful Series B financing round in 2019, in which it secured $50 million in investments, the company eventually attracted the attention of big pharma.

By December 2020, it was acquired by Eli Lilly (LLY) for $880 million with the promise to help the smaller biotech company develop three of its most promising Parkinson’s candidates.

Another Parkinson’s-centered biotech company is Axovant Gene Therapies, which has been working on a single-dose treatment for neurodegenerative disease.

Its pipeline proved to be promising, as seen in its $74.7 million public offering just last February 2020, with the company maintaining its solid footing amid the pandemic.

By November, it rebranded itself as Sio Gene Therapies (SIOX).

Outside the US is Irish biotech firm Inflazome, which is working on a unique treatment for Parkinson’s.

Unlike the other candidates, the goal of Inflazome’s drug is to directly deliver the treatment to the affected neurons. That is, it plans to pass through the blood-brain barrier.

Its research attracted the Michael J. Fox Foundation, which granted it $1 million in funding, in March 2019.

Since then, the company’s progress has attracted the attention of other major biopharmaceutical companies with Roche (RHHBY), ultimately landing the acquisition in September 2020.

Of course, talks about neurodegenerative diseases wouldn’t be complete without Biogen.

On top of its Alzheimer’s work, the Massachusetts biotechnology giant has been collaborating with San Francisco-based Parkinson’s company Denali Therapeutics.

The two have been working on the development of three small molecular drugs for $560 million in upfront payments plus $465 million in equity investment into the smaller biotech.

In addition to these, we’re still waiting on what the rest of the major biopharmaceutical companies would come up with in the future.

Given that the likes of AbbVie (ABBV), Merck (MRK), Pfizer (PFE), and AstraZeneca (AZN) have all signed up publicly via the Critical Path for Parkinson's (CPP) consortium to tackle this debilitating disease, it’s safe to say that there’s hope for the future of this sector.

 

bayer

 

bayer

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-22 15:00:352021-07-31 02:57:00Another Step Closer to Neuro-Victory
Mad Hedge Fund Trader

July 22, 2021

Diary, Newsletter, Summary

Global Market Comments
July 22, 2021
Fiat Lux

Featured Trade:

(HOW DID THOSE TECH LEAPS WORK OUT?)
(AAPL), (AMZN), (MSFT)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-22 09:04:132021-07-22 10:43:50July 22, 2021
Mad Hedge Fund Trader

How Did Those Tech LEAPS Work Out?

Diary, Newsletter

A month ago, I sent you a research piece about the merits of long-term LEAPS in the major technology stocks (click here for the link).

They included:

Amazon (AMZN) January 2022 $3,200-$3,400 vertical bull call spread

Microsoft (MSFT) January 2022 $240-$270 vertical bull call spread

Apple (AAPL) January 2022 $120-$130 vertical bull call spread

So, how did those work out? Here is the stock performance and the LEAPS performance for each position:

Amazon (AMZN) stock +11.40% LEAPS +26.79%

Microsoft (MSFT) stock +7.69% LEAPS +35.38%

Apple (AAPL) stock +13.38% LEAPS +30.92%

In other words, the LEAPS outperformed the stock to the upside by anywhere from 2.5X to 5X. All three positions are now deep-in-the-money. As long as the stocks close at or above the upper strike prices by the January 16, 20222 option expiration day, they will all produce profits of 100% or more in only seven months!

It goes to confirm the strategy that I have been vociferously arguing in recent months, that LEAPS offer far and away the best risk/reward of any investment in current market conditions. Whenever I have a payday, I pour the money straight into my retirement funds and into the most attractive LEAPS.

The liquidity for long-dated options is not that great. That is why entering limit orders in LEAPS only, as opposed to market orders, is crucial.

These are really for your buy-and-forget investment portfolio, defined benefit plan, 401k, or IRA.

Like all options contracts, LEAPS give its owner the right to exercise the option to buy or sell 100 shares of stock at a set price for a given time.

LEAPS have been around since 1990, and trade on the Chicago Board Options Exchange (CBOE).

To participate, you need an options account with a brokerage house, an easy process that mainly involves acknowledging the risk disclosures that no one ever reads.

If LEAPS expire "out-of-the-money" on expiration day, you can lose all the money you spent on the premium to buy it. There's no toughing it out waiting for a recovery, as with actual shares of stock. Poof, and your money is gone.

Note that a LEAPS owner does not vote proxies or receive dividends because the underlying stock is owned by the seller, or "writer," of the LEAPS contract until the LEAPS owner exercises.

Despite the Wild West image of options, LEAPS are actually ideal for the right type of conservative investor.

They offer vastly more margin and more efficient use of capital than traditional broker margin accounts. And you don’t have to pay the usurious interest rates that margin accounts usually charge.

And for a moderate increase in risk, they present hugely outsized profit opportunities.

For the right investor, they are the ideal instrument.

So, let’s get on with my specific math for the (AMZN) LEAPS to discover its inner beauty.

By now, you should all know what vertical bull call spreads are. If you don’t, then please click this link for my quickie video tutorial (you must be logged in to your account). Warning: I have aged since I made this video.

A month ago, Amazon closed at $3,346.83.

The cautious investor should have bought the (AMZN) January 2022 $3,200-$3,400 vertical bull call debit spread for $102. One contract gets you a $10,000 exposure. This is a bet that (AMZN) shares will close at $3,400 or higher by the January 22, 2022, option expiration, some 1.6% higher.

Sounds like a total no-brainer, doesn’t it?

Here are the specific trades you needed to execute this position:

expiration date: January 21, 2022

Portfolio weighting: 10%

Number of Contracts = 1 contract

Buy 1 January 2022 (AMZN) $3,200 call at………..….……$374.00
Sell short 1 January 2022 (AMZN) $3,400 call at…………$272.00
Net Cost:………………………….………..………….............….....$102.00

Potential Profit: $200.00 - $102.00 = $98.00

(1 X 100 X $98.00) = $9,800 or 96.07% in six months.

In other words, your $10,200 investment turned into $19,800 with an almost sure bet giving you a profit of 96.07%.
 
Why do a vertical bull call debit spread instead of just buying the January 2022 (AMZN) $3,400 calls outright?

You need a much bigger upside move to make money on this trade. (AMZN) would have to rise all the way to $3,674 to break even on the calls, and all the way up to $3,772 to match the profit of the call spread.

While I think it is possible that (AMZN) could rise that much by January, it is vastly more probable that (AMZN) will be over $3,400 by then. That is what hedge funds do all day long, and that is to find the most probable trade out there and then leverage up like crazy.

Remember, one call option gives you the right to buy 100 shares. That means over $3,400 your call spread that cost $10,200 will enable you to control 100 shares of Amazon worth $340,000. The potential upside leverage over $3,400 is 33.33X!

By paying only $102 for the spread instead of $274.00 for an outright call-only position, you can increase your size by 2.68 times, from 1 to 3 contracts for the same $10,200 commitment. That triples your upside leverage on the most probable move in (AMZN), the one above $3,400. That increases the upside leverage over $3,400 to an impressive 100X compared to the outright call buy.

How could this trade go wrong?

There is only one thing. We get a new variant on Covid-19 that overcomes the existing vaccines and brings a fourth wave in the pandemic.

In this case, (AMZN) doesn’t rise above $3,400 but crashes down to the $1,700 low we saw during the 2020 pandemic. We go back into recession. Both of the above positions go to zero. But if we get a fourth wave, you are going to have much bigger problems than your options positions.

So there it is. You pay your money and take your chances. That's why the potential returns on these simple trades are so incredibly high.

If you are interested in getting a more dedicated LEAPS service from the Mad Hedge Fund Trader, you might consider our Concierge service, which costs $10,000 a year and is by application only. If interested, please email support@madhedgefundtrader.com and put Concierge candidate in the subject line.

Enjoy.

John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

Tech LEAPS are the Way to Go

 

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2017/09/john-pogo2.jpg 605 365 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-22 09:02:282021-12-07 19:16:50How Did Those Tech LEAPS Work Out?
Mad Hedge Fund Trader

July 22, 2021 - Quote of the Day

Diary, Newsletter, Quote of the Day

“Language does not provide the means for us to describe the destruction before us,” said Chancellor Angela Merkel about the damage from the climate change-induced flooding in Germany.

https://www.madhedgefundtrader.com/wp-content/uploads/2021/07/desctruction.png 364 646 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-22 09:00:452021-07-22 10:41:36July 22, 2021 - Quote of the Day
Mad Hedge Fund Trader

July 21, 2021

Tech Letter

Mad Hedge Technology Letter
July 21, 2021
Fiat Lux

Featured Trade:

(THE TRUTH ABOUT AUTOMATION AND WALL STREET JOBS)
(AAPL), (SQ), (AMZN), (PYPL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-07-21 14:04:362021-07-21 16:25:46July 21, 2021
Page 3 of 11‹12345›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top